Trump's Pharmaceutical Sales Overhaul Benefits Son's Company and Cabinet Member
Trump’s proposed direct pharmaceutical sales to consumers would specifically benefit BlinkRx, where Donald Trump Jr. serves on the board, and Cantor Fitzgerald, connected to Commerce Secretary Howard Lutnick’s family. The policy change represents textbook corruption: government officials using regulatory authority to create markets and competitive advantages for their own business interests and those of family members. This demonstrates the systematic transformation of federal policy-making into a profit center for the Trump family and political allies.
Key Actors
Sources (1)
- Trump Wants to Overhaul Drug Sales; Company Tied to His Son Stands to Benefit - Wall Street Journal (2025-10-10) [Tier 1]
Help Improve This Timeline
Found an error or have additional information? You can help improve this event.
Edit: Opens GitHub editor to submit corrections or improvements via pull request.
Suggest: Opens a GitHub issue to propose a new event for the timeline.